Ameriprise
RYTM icon

Ameriprise’s Rhythm Pharmaceuticals RYTM Stock Holding History

Ameriprise’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.6M Buy
401,634
+17,677
+5% +$1.6M 0.01% 1006
2026
Q1 		$33.4M Buy
383,957
+122,797
+47% +$11.9M 0.01% 1087
2025
Q4 		$28M Buy
261,160
+123,193
+89% +$13.1M 0.01% 1183
2025
Q3 		$13.9M Sell
137,967
-35,102
-20% -$3.26M ﹤0.01% 1659
2025
Q2 		$10.9M Buy
173,069
+74,788
+76% +$4.58M ﹤0.01% 1750
2025
Q1 		$5.21M Buy
98,281
+44,914
+84% +$2.49M ﹤0.01% 2284
2024
Q4 		$2.99M Buy
53,367
+11,480
+27% +$634K ﹤0.01% 2696
2024
Q3 		$2.19M Buy
41,887
+1,472
+4% +$70.5K ﹤0.01% 2871
2024
Q2 		$1.66M Buy
40,415
+19,435
+93% +$776K ﹤0.01% 2946
2024
Q1 		$909K Hold
20,980
– – ﹤0.01% 3204
2023
Q4 		$964K Sell
20,980
-1,000
-5% -$31.5K ﹤0.01% 3202
2023
Q3 		$504K Buy
21,980
+3,840
+21% +$86K ﹤0.01% 3414
2023
Q2 		$299K Hold
18,140
– – ﹤0.01% 3607
2023
Q1 		$324K Hold
18,140
– – ﹤0.01% 3590
2022
Q4 		$528K Hold
18,140
– – ﹤0.01% 3388
2022
Q3 		$445K Hold
18,140
– – ﹤0.01% 3440
2022
Q2 		$75K Buy
+18,140
New +$99.3K ﹤0.01% 3810
2021
Q1 		– Sell
-8,410
Closed -$250K – 3892
2020
Q4 		$250K Buy
+8,410
New +$214K ﹤0.01% 3572
2020
Q1 		– Sell
-12,610
Closed -$290K – 3724
2019
Q4 		$290K Sell
12,610
-25,000
-66% -$555K ﹤0.01% 3486
2019
Q3 		$812K Buy
+37,610
New +$807K ﹤0.01% 3103

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ameriprise's RYTM Position: Q2 2026 in Review

Ameriprise increased its Rhythm Pharmaceuticals (RYTM) stake by 4.6% in Q2 2026, buying an estimated $1.6M and bringing the position to 401,634 shares worth $44.6M. The position accounts for 0.01% of the portfolio, ranked #1006.

Ameriprise first reported a position in RYTM in Q3 2019 and has held it in 20 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Ameriprise held 401,634 shares of Rhythm Pharmaceuticals worth $44.6M as of Q2 2026.
  • Ameriprise bought 17,677 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $1.6M.
  • Rhythm Pharmaceuticals made up 0.01% of Ameriprise's portfolio in Q2 2026, its #1006 holding.
  • Ameriprise first reported a position in Rhythm Pharmaceuticals in Q3 2019 and has held it in 20 quarters since.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.